VExUS in Ards Patients and Association with AKI

ConditionAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-100

SponsorAssistance Publique - Hôpitaux de Paris

About this trial

A single-center prospective observational study will be conducted with the aim of determining the prevalence of venous congestion during ARDS using venous Doppler and the VExUS score.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients ≥18 years old

Moderate to severe ARDS according to the Berlin definition

Requiring catecholamine support

Undergoing invasive mechanical ventilation for less than 48 hours

Disqualifiers

Patients presenting with acute kidney injury KDIGO III requiring renal replacement therapy before the initial ultrasound evaluation

Requirement for veno-venous or veno-arterial ECMO circulatory support before inclusion

Patients with end-stage chronic kidney disease, on dialysis, and/or kidney transplant recipients

History of Child C cirrhosis and/or liver transplantation and/or portal hypertension

Trial population

The study concerns adult patients hospitalized in intensive care for moderate to severe ARDS according to the Berlin definition, and requiring hemodynamic support with catecholamineEKG

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

Proportion of VExUS score ≥ 1 within 48 hours of invasive mechanical ventilation.

Quantification of the VExUS score from the measurement of the inferior vena cava size, an assessment of suprahepatic venous flow, portal venous flow and intra-renal venous.

Time frame

48 hours, 7 days after mechanical ventilation

Secondary outcomes

Occurrence of the composite endpoint of major kidney events at Day 30 (MAKE-30).

defined as death, dependence on dialysis, or persistence of a creatinine elevation ≥ 200% of baseline creatinine.

Time frame

30 days

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Source ClinicalTrials.gov

Apply now